Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428
Conditions
COVID-19, SARS-CoV-2
Interventions
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Conditions
COVID-19
Interventions
Dapsone 85 mg PO BID, Placebo 85 mg PO BID
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
40 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Conditions
Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions
IV normal saline, IV immunoglobulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers Results available

Home Usability Study of the SARS-CoV-2 (COVID-19) Test

NCT04395391
Conditions
COVID-19
Interventions
SARS-CoV-2
Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
774 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
19
States / cities
Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more
Completed Phase 2 Interventional Results available

Fostamatinib for Hospitalized Adults With COVID-19

NCT04579393
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
COVID-19, Sars-CoV2
Interventions
COVID-19 Convalescent Plasma (CCP), Placebo
Biological
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 3 Interventional Accepts healthy volunteers

A Strain Change Study for SARS-CoV-2 rS Vaccines

NCT06409663
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions
NVX-CoV2705 Vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Austin, Texas
Conditions
Severe Acute Respiratory Syndrome
Interventions
Otilimab, Placebo 1, Placebo 2, Standard of care
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Conditions
Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions
Alteplase 50 MG [Activase]
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Completed Phase 2 Interventional Results available

Paxlovid for Treatment of Long Covid

NCT05576662
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Interventions
Nirmatrelvir, Placebo, Ritonavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Focal Mask
Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Conditions
Healthy
Interventions
PF-07304814
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
COVID-19
Interventions
Brequinar, Standard of Care
Drug · Other
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 2 more
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pancoronavirus Vaccine Study in Healthy Adults

NCT06950177
Conditions
COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
Interventions
CoV-RBD-scNP-001 and 3M-052-AF
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina